Second District Affirms Denial of Nexium Marketing Class Action
In Weiss v. AstraZeneca Pharmaceuticals et al., No. B215901,2010 WL 3387220 (Cal. Ct. App. 2d Dist. Aug. 30, 2010), the Second District affirmed denial of class certification and summary judgment in favor of defendants relating to the alleged deceptive marketing of the prescription drug Nexium.